Results 151 to 160 of about 6,775 (167)

Resistance to obinutuzumab-induced antibody-dependent cellular cytotoxicity caused by abnormal Fas signaling is overcome by combination therapies

Molecular Biology Reports, 2022
Yoriko Yamashita-Kashima, Natsumi Kawasaki, Naoki Harada   +2 more
exaly  

Obinutuzumab

Reactions Weekly, 2016
openaire   +2 more sources

Obinutuzumab

Drugs of the Future, 2011
null Karlin, L., null Salles, G.
openaire   +1 more source

Cost–effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma

Journal of Comparative Effectiveness Research, 2023
Wendong Chen
exaly  

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Lancet, The, 2020
Jeff Sharman, John Pagel, Ian Flinn
exaly  

Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis

Leukemia and Lymphoma, 2020
Xuehong Ran, Hongguang Zhu
exaly  

Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View

Value in Health, 2023
Frederick Wilhelm Thielen
exaly  

Obinutuzumab‐related adverse events: A systematic review and meta‐analysis

Hematological Oncology, 2021
Pia Raanani, Liat Shargian, Irina Amitai   +2 more
exaly  

Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases

American Journal of Kidney Diseases, 2020
Ladan Zand, Nattawat Klomjit
exaly  

<p>Clinical application of obinutuzumab for treating chronic lymphocytic leukemia</p>

Drug Design, Development and Therapy, 2019
Baoan Chen
exaly